Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced its financial results for the quarter and nine months ended September 30, 2007. Financial information presented represents the consolidated results of IDM Pharma and its subsidiary, IDM S.A.

Cash and cash equivalents totaled $33.2 million as of September 30, 2007 compared to $37.3 million on June 30, 2007 and $10.2 million on December 31, 2006. The Company's net cash outflow from operations and investment activities for the quarter and nine months ended September 30, 2007, which excludes cash received from financing activities and the effect of exchange rates, was approximately $5.1 million and $14.3 million, respectively.

"During the third quarter we announced our intention to collect additional survival data from the L-MTP-PE Phase 3 trial and submit an amendment to the NDA in the first quarter of 2008," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "In addition, we announced the appointment of Jeff Sherman as our chief medical officer who brings valuable expertise to the management team as we work through the regulatory approval process for L-MTP-PE in the U.S. and Europe, and as we develop our oncology pipeline."

Quarter Ended September 30, 2007

Total revenues in the third quarter of 2007 were $3.1 million compared to total revenues of $3.0 million for the quarter ended September 30, 2006. Substantially all of the revenues for both periods were derived from the Company's collaboration agreement with sanofi-aventis. The $0.1 million increase in revenues in the 2007 period was due to an increase in development costs related to UVIDEM clinical trials, which are reimbur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 This Latest Guidebook for Conducting ... (2014 Edition) not only provided a comprehensive and thorough ... for imported drug registration but also introduced the practical ... guide you to use the Chinese trial venues to ... world step by step. , The audiences of this ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The ... (SQL, Nosql), Software (Database Application Builder, Data Scaling ... Models (Iaas, Paas, Dbaas) and Service Models (Public ... & Organization Size (Small And Medium, Large) - ... and segments the global cloud database and DBaaS ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Mortality rates increase due to extreme heat and cold 2Health News:CRN International Names New Director to Lead Client Services Department 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4
... state Health Directorate officials have confirmed that there has ... fever in about 29// villages of Nasik district. Around ... have been hospitalized. ,Malegon was the worst ... were sent to the National Institute of Virology (NIV), ...
... physician from Philadelphia has come out with a ... from arthritis. The technique when used will ease ... ,Interventional radiologist Kevin Baskin of Children's Hospital ... ankle joint of juvenile arthritis patients at the ...
... Pakistan's 155 million population carries the deadly hepatitis virus, ... ,"Hepatitis B and C is a time bomb ... to control it," said the president of the Pakistan ... 2006 report. ,The association represents medical practitioners ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... covering the provinces of Luanda, Bengo, Benguela, and Kwanza Norte. ... 13, the number of reported cases has risen to 2,026 ... Sunday WHO representative, Angola Fatoumata Diallo handed over 7 ... of Health Jose Van- Dunem. ,The National Laboratory ...
... showed that ROZEREM? (ramelteon) could be used for treating people ... reduce the time to fall asleep in adults significantly. // ... showed no signs of recurring or withdrawal effects. ... 8 mg of ROZEREM experienced at least a 50 percent ...
Cached Medicine News:Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 2Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 3Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 4
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first,natural compound to ... on stroke,recovery starting in the acute stage. ... trial to evaluate the efficacy of NeuroAid(TM) in ... with treatment starting within 48 hours of a ...
... 26 Rcadia Medical Imaging, Ltd.,developer of novel ... Food and Drug Administration (FDA) clearance to market,its ... triaging patients for,coronary artery disease (CAD). The new ... human intervention and automatic detection of,pathologies in the ...
Cached Medicine Technology:International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 2International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 3International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 4Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance 2
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: